natgillin/translations-raw huggingface dataset:
However, due to the results of animal studies in breast-feeding mothers and neonates (see section 5.3), breast-feeding is contra-indicated in women taking CYSTAGON. 
Međutim, zbog rezultata ispitivanja provedenih na životinjama koje su dojile i njihovoj mladunčadi (vidjeti dio 5.3), dojenje je kontraindicirano u žena koje uzimaju CYSTAGON.
Cystine build up causes kidney damage and excretion of excess amounts of glucose, proteins and electrolytes. 
Nagomilani cistin dovodi do oštećenja bubrega i izlučivanja prekomjernih količina glukoze, proteina i elektrolita.
100 hard capsules (with a desiccant unit in the bottle) 500 hard capsules (with a desiccant unit in the bottle) 
100 tvrdih kapsula (sa sredstvom za sušenje u bočici) 500 tvrdih kapsula (sa sredstvom za sušenje u bočici)
Very limited data suggest that cysteamine pharmacokinetic parameters may not be significantly modified in patients with mild to moderate renal insufficiency. 
Vrlo ograničeni podaci upućuju na to da farmakokinetički parametri cisteamina nisu značajno promijenjeni kod bolesnika s blagim do umjerenim zatajenjem bubrega.
- Your doctor could require controlling the blood cell count on a regular basis. 
- Vaš liječnik može zahtijevati redovitu kontrolu krvne slike.
There are no adequate data from the use of cysteamine bitartrate in pregnant women. 
Ne postoje adekvatni podaci o primjeni cisteamin bitartrata u trudnica.
A reduction of fertility was observed in rats at 375 mg/kg/day, a dose at which body weight gain was retarded. 
Kod štakora je zabilježeno smanjenje fertiliteta pri 375 mg/kg/dan, dozi pri kojoj je bio usporen prirast tjelesne težine.
Bottles of 100 or 500 hard capsules. 
Bočice sa 100 ili 500 tvrdih kapsula.
Nephropathic cystinosis must have been diagnosed by both clinical signs and biochemical investigations (leucocyte cystine measurements). 
Nefropatska cistinoza mora biti dijagnosticirana na temelju i kliničkih znakova i biokemijskih pretraga (mjerenja cistina u leukocitima).
Teratogenic effects have been described in rats when cysteamine is administered over the period of organogenesis at a dose of 100 mg/kg/day. 
Teratogeni učinci su opisani kod štakora kada je cisteamin primijenjen tijekom razdoblja organogeneze u dozi od 100 mg/kg/dan.
Cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation. 
Zabilježeni slučajevi nefrotskog sindoma unutar 6 mjeseci od započinjanja terapije s progresivnim oporavkom nakon prekida liječenja.
CYSTAGON therapy must be initiated promptly after confirmation of the diagnosis of nephropathic cystinosis to achieve maximum benefit. 
Liječenje CYSTAGONOM treba započeti odmah nakon potvrde dijagnoze nefropatske cistinoze kako bi se postigla maksimalna korist.
CYSTAGON should be taken or given only by mouth and exactly as your or your child's doctor directs. 
CYSTAGON treba uzimati ili davati samo na usta i točno kako Vam je Vaš liječnik ili liječnik Vašeg djeteta odredio.
Genotoxicity studies have been performed: although in published studies using cysteamine, induction of chromosome aberrations in cultured eukaryotic cell lines has been reported, specific studies with cysteamine bitartrate did not show any mutagenic effects in the Ames test or any clastogenic effect in the mouse micronucleus test. 
Provedena su ispitivanja genotoksičnosti: iako je u objavljenim ispitivanjima s cisteaminom zabilježeno izazivanje kromosomskih aberacija u kulturama eukariotskih staničnih linija, specifična ispitivanja s cisteamin bitartratom nisu pokazala mutagene učinke u Amesovom testu ili bilo kakav klastogeni učinak u mikronukleus testu na mišu.
In any case the usual dose should not exceed 1.95 g/m2/day. 
U nijednom slučaju doza ne smije prelaziti 1,95 g/m2/dan.
This is equivalent to 0.6 g/m2/day in the rat, which is less than half the recommended clinical maintenance dose of cysteamine, i.e. 1.30 g/ m2/day. 
Ovo je ekvivalentno dozi od 0,6 g/m2/dan kod štakora, što je manje od polovice preporučene kliničke doze održavanja za cisteamin, tj. 1,30 g/ m2/dan.
The plasma protein binding in patients at steady state is similar: 53.1 % ( 3.6) and 51.1 % ( 4.5) at 1.5 and 6 hours post-dose, respectively. 
Vezanje za proteine plazme kod bolesnika u stanju dinamičke ravnoteže je slično: 53,1 % ( 3,6) odnosno 51,1 % ( 4,5) nakon 1,5 odnosno 6 sati od primjene doze.
Digestive tolerance of cysteamine is improved when the medicinal product is taken just after or with food. 
Podnošenje cisteamina od strane probavnog sustava poboljšano je kada se ovaj lijek uzima neposredno nakon ili tijekom obroka.
Indomethacin and CYSTAGON have been used simultaneously in some patients. 
U nekih su bolesnika istodobno korišteni indometacin i CYSTAGON.
In cases where histopathological examination of the skin was performed, the results suggested angioendotheliomatosis. 
U slučajevima u kojim je proveden histopatološki pregled kože, rezultati su upućivali na angioendoteliomatozu.
In cases of patients with kidney transplants, anti-rejection treatments have been used with cysteamine. 
U bolesnika s transplantiranim bubrezima, terapija protiv odbacivanja transplantata korištena je s cisteaminom.
- Regular blood tests to measure the amount of cystine inside white blood cells are necessary to help determine the correct dose of CYSTAGON. 
- Neophodne su redovite krvne pretrage radi mjerenja cistina unutar leukocita da bi pomogle odrediti ispravnu dozu Cystagona.
Keep the container tightly closed in order to protect from light and moisture 
Spremnik čuvati čvrsto zatvoren radi zaštite od svjetlosti i vlage.
• For patients over age 12 and over 50 kg weight, the recommended CYSTAGON dose is 2 g/day, divided four times daily. 
• Za bolesnike iznad 12 godina i preko 50 kg tjelesne težine, preporučena doza CYSTAGONA je 2 g/dan, podijeljena u četiri puta na dan.
If any similar skin or bone abnormalities appear, it is recommended to decrease the dose of CYSTAGON. 
Ukoliko se pojave bilo koje slične abnormalnosti kože ili kostiju, preporučuje se smanjiti dozu CYSTAGONA.
You may already be receiving phosphate supplements and the dose of these may need to be changed when CYSTAGON is substituted for phosphocysteamine. 
Možda već primate nadomjestke fosfata te će njihovu dozu možda trebati promijeniti kada se CYSTAGON zamijeni fosfocisteaminom.
In children who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food. 
U djece kod koje postoji rizik od aspiracije, u dobi oko 6 godina i mlađe, tvrde kapsule treba otvoriti, a sadržaj posipati po hrani.
The leucocyte cystine level reaches its minimum (mean ( sd) value: 1.8  0.8 hours) slightly later than the peak plasma cysteamine concentration (mean ( sd) value: 1.4  0.4 hours) and returns to its baseline level as the plasma cysteamine concentration decreases at 6 hours post-dose. 
Razina cistina u leukocitima postiže svoj minimum (srednja vrijednost ( sd): 1,8  0,8 sati) nešto kasnije od postizanja vršne koncentracije cisteamina u plazmi (srednja vrijednost ( sd): 1,4  0,4 sati) te se vraća na bazalnu razinu kako se koncentracija cisteamina u plazmi smanji 6 sati nakon uzete doze.
At this dose, weight gain and survival of the offspring during lactation was also reduced. 
Pri ovoj dozi, također su bili smanjeni prirast tjelesne težine te preživljavanje potomaka tijekom dojenja.
Common: Headache, encephalopathy Uncommon: Somnolence, convulsions 
Često: Glavobolja, encefalopatija Manje često: Somnolencija, konvulzije
An earlier study treated 94 children with nephropathic cystinosis with increasing doses of cysteamine to attain white cell cystine levels of less than 2 nmol hemicystine/mg protein 5 to 6 hours post-dose, and compared their outcome with an historical control group of 17 children treated with placebo. 
U ranijoj studiji 94 djece s nefropatskom cistinozom liječeno je rastućim dozama cisteamina da bi se održala razina cistina u leukocitima ispod 2 nmol hemicistina/mg proteina 5 do 6 sati nakon uzimanja doze te je ishod kod njih uspoređen s povijesnom kontrolnom skupinom od 17-tero djece koja su primala placebo.
Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure. 
Cisteamin smanjuje nakupljanje cistina u nekim stanicama (npr. leukocitima, mišićnim i jetrenim stanicama) kod bolesnika s nefropatskom cistinozom te, ukoliko je liječenje rano započeto, odgađa nastanak zatajenja bubrega.
High doses of cysteamine impair the ability of lactating mothers to feed their pups. 
Visoke doze cisteamina oštećuju sposobnost ženki u laktaciji da hrane svoje mladunce.
It is not known if cysteamine is removed by haemodialysis. 
Nije poznato da li se cisteamin odstranjuje hemodijalizom.
In one clinical study, baseline white cell cystine levels were 3.73 (range 0.13 to 19.8) nmol hemicystine/mg protein and were maintained close to 1 nmol hemicystine/mg protein with a cysteamine dose range of 1.3 to 1.95 g/m2/day. 
U jednom kliničkom ispitivanju, bazalna razina cistina u leukocitima iznosila je 3,73 (raspon 0,13 do 19,8) nmol hemicistina/mg proteina te je održavana blizu 1 nmol hemicistina/mg proteina uz raspon doza cisteamina od 1,3 do 1,95 g/m2/dan.
CYSTAGON may cause some drowsiness. 
CYSTAGON može dovesti do pospanosti.
In some cases, histology showed a membranous glomerulonephritis of the renal allograft and hypersensitivity interstitial nephritis. 
U nekim slučajevima, histologija je pokazala membranozni glomerulonefritis alogeničnog bubrežnog presatka te hipersenzitivni intersticijski nefritis.
Most patients will already be receiving phosphate supplements and the dose of these may need to be altered when CYSTAGON is substituted for phosphocysteamine. 
Većina će bolesnika već primati nadomjestke fosfata te može biti potrebno prilagoditi njihovu dozu kada se CYSTAGON zamijeni fosfocisteaminom.
What CYSTAGON is and what it is used for Before you use CYSTAGON How to use CYSTAGON Possible side effects 
Što je CYSTAGON i za što se koristi Prije nego počnete primjenjivati CYSTAGON
- Very common: vomiting, nausea, diarrhoea, loss of appetite, fever and sensation of sleep 
- Vrlo često: povraćanje, mučnina, proljev, gubitak apetita, vrućica i osjećaj pospanosti
• For children up to age 12 years, CYSTAGON dosing should be on the basis of body surface area (g/m 2/day). 
• Za djecu do 12 godina, CYSTAGON treba dozirati na temelju površine tijela (g/m 2/dan).
The decrease in leucocyte cystine levels is correlated to the cysteamine plasma concentration over the six hours following the administration of CYSTAGON. 
Pad razine cistina u leukocitima korelira s koncentracijom cisteamina u plazmi kroz šest sati nakon primjene CYSTAGONA.
Monitoring of blood cell count is recommended on a regular basis. 
Savjetuje se redovito praćenje krvne slike.
- In contrast to phosphocysteamine, another active substance close to cysteamine bitartrate, CYSTAGON does not contain phosphate. 
Za razliku od fosfocisteamina, druge djelatne tvari bliske cisteaminditartratu, CYSTAGON ne sadrži fosfat.
The dose should be raised if there is adequate tolerance and the leucocyte cystine level remains >1 nmol hemicystine/mg protein. 
Dozu treba povećati ako je tolerancija dobra, a razina cistina u leukocitima ostane >1 nmol hemicistina/mg proteina.
Breast-feeding CYSTAGON must not be used during breast-feeding. 
Dojenje CYSTAGON se ne smije koristiti tijekom dojenja.
The in vitro plasma protein binding of cysteamine, which is mostly to albumin, is independent of plasma drug concentration over the therapeutic range, with a mean ( sd) value of 54.1 % ( 1.5). 
Vezanje cisteamina za proteine plazme in vitro, a većinom se veže za albumin, unutar terapijskog raspona neovisno je o koncentraciji lijeka u plazmi, sa srednjom vrijednosti ( sd) od 54,1 % ( 1,5).
Experience has occasionally shown that some forms of cysteamine are less well tolerated (i.e. leading to more adverse events) when patients are on dialysis. 
Iskustvo je povremeno pokazalo da se neki oblici cisteamina lošije podnose (tj. dovode do više nuspojava) kad su bolesnici na dijalizi.
It is therefore recommended to monitor regularly skin and to consider X-ray examinations of the bone as necessary. 
Stoga se preporučuje redovito kontrolirati kožu te po potrebi razmotriti rendgenske preglede kostiju.
Reproduction studies showed embryofoetotoxic effects (resorptions and post-implantation losses) in rats at the 100 mg/kg/day dose level and in rabbits receiving cysteamine 50 mg/kg/day. 
Reproduktivna ispitivanja pokazala su embriofetotoksične učinke (resorpcije te gubitke nakon implantacije) kod štakora pri razini doza od 100 mg/kg/dan te kod kunića koji su primali cisteamin od 50 mg/kg/dan.
Following a single oral dose of cysteamine bitartrate equivalent to 1.05 g of cysteamine free base in healthy volunteers, the mean ( sd) values for the time to peak and peak plasma concentration are 1.4 ( 0.5) hours and 4.0 ( 1.0) µg/ml, respectively. 
Nakon pojedinačne oralne doze cisteamin bitartrata koja je ekvivalentna 1,05 g slobodne baze cisteamina kod zdravih dobrovoljaca, srednje vrijednosti ( sd) za vrijeme potrebno za postizanje vršne koncentracije te za postizanje vršne koncentracije u plazmi iznose 1,4 ( 0,5) sati odnosno 4,0 ( 1,0) µg/ml.
CYSTAGON has minor or moderate influence on the ability to drive and use machines CYSTAGON may cause drowsiness. 
CYSTAGON malo ili umjereno utječe na sposobnost upravljanja vozilima i rada na strojevima.
How to store CYSTAGON Further information 
Kako čuvati CYSTAGON Dodatne informacije
Uncommon: Anaphylactic reaction 
Manje često: Anafilaktička reakcija
- Uncommon: skin striae, skin lesion (little-hard lumps on elbows), joint laxity, leg pain, bone fracture, scoliosis (deviation of the vertebral column), bone deformity and fragility, hair discoloration, severe allergic reaction, somnolence, fits, nervousness, hallucination, decrease in white blood cells, gastrointestinal ulcer manifested by bleeding in the digestive tract and effect on the kidney manifested by swelling of the extremities and weight gain. 
- Manje često: strije na koži, lezije kože (male tvrde kvržice na laktovima), labavost zglobova, bol u nogama, prijelom kosti, skolioza (iskrivljenje kralježnice), deformacija i lomljivost kostiju, promjena boje kose, teška alergijska reakcija, pospanost, napadaji, nervoza, halucinacije, smanjen broj bijelih krvnih stanica, čir na želucu ili crijevima koji se očituje krvarenjem u probavnom sustavu te učinak na bubreg koji se očituje oticanjem udova i porastom tjelesne težine.
CYSTAGON should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.6 and section 5.3), as it is teratogenic in animals. 
CYSTAGON se ne smije koristiti tijekom trudnoće, osobito tijekom prvog tromjesečja, osim ako nije izričito neophodan (vidjeti dio 4.6 te dio 5.3), jer je teratogen kod životinja.
CYSTAGON treatment should be initiated under the supervision of a physician experienced in the treatment of cystinosis. 
Liječenje CYSTAGONOM treba započeti pod nadzorom liječnika s iskustvom u liječenju cistinoze.
For patients over age 12 and over 50 kg weight, the usual dose is 2g/day. 
Kod bolesnika starijih od 12 godina te s više od 50 kg tjelesne težine, uobičajena doza je 2g/dan.
Single doses of the drug inhibit prolactin secretion in animals. 
Pojedinačne doze lijeka inhibiraju izlučivanje prolaktina kod životinja.
In some the patients, the skin lesions on elbows regressed after CYSTAGON dose reduction. 
U nekih bolesnika, kožne promjene na laktovima su se povukle nakon smanjenja doze CYSTAGONA.
Treatment with CYSTAGON should continue indefinitely, as instructed by your doctor. 
Liječenje lijekom CYSTAGON treba nastaviti do daljnjeg, kao što Vam je savjetovao Vaš liječnik.
Oral cysteamine has not been shown to prevent eye deposition of cystine crystals. 
Nije se pokazalo da oralni cisteamin sprječava odlaganje kristala cistina u očima.
HDPE bottles of 100 and 500 hard capsules. 
HDPE bočice sa 100 i 500 tvrdih kapsula.
In some cases, these skin lesions were associated with vascular proliferation, skin striae and bone lesions first seen during an X-ray examination. 
U nekim slučajevima, ove kožne promjene povezivale su se s vaskularnom proliferacijom, strijama na koži i lezijama kostiju koje su prvo zabilježene tijekom rendgenskog pregleda.
White blood cell (WBC) cystine levels should therefore be monitored to adjust the dose. 
Stoga treba pratiti razinu cistina u leukocitima (Lkc) kako bi se prilagodila doza.
The use of doses higher than 1.95g/m2/day is not recommended (see sections 4.2 and 4.8). 
Ne preporuča se upotreba doza viših od 1,95g/m2/dan (vidjeti dijelove 4.2 i 4.8).
High doses of cysteamine, either by oral or parenteral routes, produce duodenal ulcers in rats and mice but not in monkeys. 
Visoke doze cisteamina, primijenjene bilo oralnim bilo parenteralnim putem, uzrokovale su ulkuse dvanaesnika kod štakora i miševa, ali ne kod majmuna.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU
CYSTAGON excretion in human's milk is unknown. 
Nije poznato da li se CYSTAGON izlučuje u majčino mlijeko u ljudi.
BEFORE YOU USE CYSTAGON 
PRIJE NEGO POČNETE PRIMJENJIVATI CYSTAGON
If you forget to take CYSTAGON: 
Ako ste zaboravili primjeniti CYSTAGON
The goal of therapy is to keep leucocyte cystine levels below 1 nmol hemicystine/mg protein. 
Cilj terapije je održati razinu cistina u leukocitima ispod 1 nmol hemicistina/mg proteina.
A closer monitoring of the leucocyte cystine levels is recommended in these patients. 
Kod ovih se bolesnika savjetuje pažljivije praćenje razine cistina u leukocitima.
CYSTAGON is indicated for the treatment of proven nephropathic cystinosis. 
CYSTAGON je indiciran za liječenje dokazane nefropatske cistinoze.
What CYSTAGON looks like and contents of the pack Hard Capsules - Cystagon 50 mg: white, opaque hard capsules with CYSTA 50 on the body and MYLAN on the cap. 
Kako CYSTAGON izgleda i sadržaj pakovanja Tvrde kapsule - Cystagon 50 mg: bijele, neprozirne tvrde kapsule s CYSTA 50 na tijelu i MYLAN na kapici.
Cysteamine reacts with cystine to form the mixed disulfide of cysteamine and cysteine. 
Cisteamin reagira s cistinom stvarajući miješani disulfid cisteamina i cisteina te cistein.
The mean white cell cystine level attained during treatment was 1.7 + 0.2 nmol hemicystine/mg protein. 
Srednja vrijednost razine cistina u leukocitima postignuta tijekom liječenja bila je 1,7 + 0,2 nmol hemicistina/mg proteina.
Common: Skin odour abnormal, rash Uncommon: Hair colour changes, skin striae, skin fragility (molluscoid pseudotumor on elbows) 
Često: Abnormalan miris kože, osip Manje često: Promjene boje kose, strije na koži, fragilnost kože (moluskoidan pseudotumor na laktovima)
Common: Liver function tests abnormal 
Često: Poremećaj testova jetrene funkcije
- Common: abdominal pain or discomfort, unpleasant breath and body odour, skin eruption, gastroenteritis, fatigue, headache, encephalopathy (brain disorder) and liver function test abnormalities. 
Često: bol ili nelagoda u trbuhu, neugodan zadah i miris tijela, kožne promjene, gastroenteritis, umor, glavobolja, encefalopatija (poremećaj mozga) i abnormalnosti testova jetrene funkcije.
What CYSTAGON contains - The active substance is cysteamine bitartrate (mercaptamine bitartrate). 
Što CYSTAGON sadrži - Djelatna tvar je cisteaminditartarat (merkaptaminditartarat).
These lesions were associated with skin striae and bone lesions such as fracture and bone deformities, and with laxity of joints. 
Ove su lezije bile povezane sa strijama na koži i lezijama kostiju poput prijeloma i deformiteta kostiju te s povećanom elastičnosti zglobova.
Capsule content: microcrystalline cellulose, pregelatinized starch, magnesium stearate/sodium lauryl sulfate, colloidal silicon dioxide, croscarmellose sodium Capsule shell: gelatin, titanium dioxide, 
Sadržaj kapsule: celuloza, mikrokristalična, škrob, prethodno geliran, magnezijev stearat/natijev laurilsulfat, silicijev dioksid, koloidni, karmelozanatrij, umrežena Ovojnica kapsule: želatina, titanijev dioksid,
Administration of cysteamine in neonate rats induced cataracts. 
Primjena cisteamina kod mladunčadi štakora dovela je do katarakti.
The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4). 
Ne preporučuje se primjena doza viših od 1,95 g/m2/dan (vidjeti dio 4.4).
In patients at steady state, these values are 1.4 ( 0.4) hours and 2.6 ( 0.9) µg/ml, respectively, after a dose ranging from 225 to 550 mg. Cysteamine bitartrate (CYSTAGON) is bioequivalent to cysteamine hydrochloride and phosphocysteamine. 
Kod bolesnika u stadiju dinamičke ravnoteže, ove su vrijednosti 1,4 ( 0,4) sati odnosno 2,6 ( 0,9) µg/ml, nakon doze u rasponu od 225 do 550 mg.
Capsule content: microcrystalline cellulose, pregelatinized starch, magnesium stearate/sodium lauryl sulfate, colloidal silicon dioxide, croscarmellose sodium Capsule shell: gelatin, titanium dioxide, black ink on hard capsules containing E172 
- Pomoćne tvari su mikrokristalična celuloza, škrob, prethodno geliran, magnezijev stearat/natrijev laurilsulfat, koloidni silicijev dioksid, umrežena karmelozanatrij, ovojnica kapsule: želatina, titanijev dioksid, crna tinta na tvrdim kapsulama (E172).
HOW TO USE CYSTAGON 
KAKO PRIMJENJIVATI CYSTAGON
Experimental administration of the drug causes depletion of somatostatin in several animal species. 
Eksperimentalna primjena lijeka kod nekoliko životinjskih vrsta dovela je do deplecije somatostatina.
Individuals with nephropathic cystinosis have elevations of white cell cystine above 2 nmol hemicystine/mg protein 
Pojedinci s nefropatskom cistinozom imaju povećane razine cistina u leukocitima preko 2 nmol hemicistina/mg proteina.
- Cystagon 150 mg: white, opaque hard capsules with CYSTAGON 150 on the body and MYLAN on the cap. 
- Cystagon 150 mg: bijele, neprozirne tvrde kapsule s CYSTAGON 150 na tijelu i MYLAN na kapici.
Normal individuals and heterozygous subjects for cystinosis have white cell cystine levels of < 0.2, and usually below 1 nmol hemicystine/mg protein, respectively. 
Normalni pojedinci imaju razinu cistina u leukocitima < 0,2, a heterozigotni ispitanici na cistinozu imaju razinu manju od 1 nmol hemicistina/mg proteina.
Bone disorders reported were genu valgum, leg pain and hyperextensive joints, osteopenia, compression fractures, and scoliosis. 
Od poremećaja kostiju zabilježeni su genu valgum, bol u nogama i hiperekstenzivni zglobovi, osteopenija, kompresijski prijelomi, i skolioza.
Cases of Ehlers-Danlos like syndrome and vascular disorders on elbows have been reported in children treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/m2/day. 
Zabilježeni su slučajevi sindroma nalik na Ehlers-Danlos i vaskularnih poremećaja na laktovima u djece koja su bila liječena visokim dozama različitih preparata cisteamina (cisteaminkloridom ili cistaminom ili cisteaminditartratom) većinom iznad maksimalne doze od 1,95 g/m2/dan.
These skin lesions were associated with vascular proliferation, skin striae and bone lesions. 
Ove su kožne promjene bile povezivane s vaskularnom proliferacijom, strijama na koži te lezijama kostiju.
- A few cases of skin lesions on elbows like little hard lumps have been reported in children treated with high doses of different cysteamine preparations. 
- Kod djece liječene visokim dozama različitih preparata cisteamina zabilježeno je nekoliko slučajeva kožnih lezija na laktovima nalik na male tvrde kvrge.
Very common: Vomiting, nausea, diarrhoea Common: Abdominal pain, breath odour, dyspepsia, gastroenteritis 
Vrlo često: Povraćanje, mučnina, proljev Često: Bol u trbuhu, zadah, dispepsija, gastroenteritis Manje često: Gastrointestinalni ulkus
Uncommon: Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis. 
Manje često: Hiperekstenzija zglobova, bol u nogama, genu valgum, osteopenija, kompresijski prijelom, skolioza.